Save 20% on your next Cambridge Bioethics and Law online purchase
Page URL: https://www.bionews.org.uk/page_94776

Revamped gene therapy for 'bubble boy' immune condition does well in trial

13 October 2014
Appeared in BioNews 775

Gene therapy to treat children with 'bubble boy syndrome' seems to be both safe and effective, a study published in the New England Journal of Medicine has found.

Eight out of nine babies treated were alive one to three years after being given the treatment, when they normally would have died before they turned one.

The children lack a gene that produces a protein vital for a functioning immune system; as this gene is found on the X chromosome this condition almost always occurs in boys. Patients with this X-linked severe combined immunodeficiency (SCID-X1) traditionally had to be kept in sterile conditions (or 'bubbles') to prevent infections.

The treatment tested was an altered version of a previous gene therapy that improved immune systems but caused leukaemia in some patients.

Professor Adrian Thrasher, who led the research at Great Ormond Street Hospital, said: 'While the long term effect on the development of cancer across the lifetime in these patients remains unknown, the changes that we have made to this vector appear hugely promising.'

Gene therapy inserts a working copy of the missing gene using a viral vector. The viruses insert their own DNA into the genome of the cell they infect, allowing them to produce the therapeutic protein for as long as that cell lives.

Initial attempts to treat bubble boys with gene therapy proved that it was possible to give these children functioning immune systems; however a quarter of these children went on to develop leukemia. It was later found that the viruses used in these early trials tended to insert themselves in the patients' genome close to certain genes, causing these genes to 'turn on'; the activation of these genes caused these cells to grow and multiply faster, leading to cancer.

This improved version of the therapeutic virus appears to be safer for two reasons: it is less likely to insert next to potentially cancer-related genes, and it is less likely to activate any nearby genes.

While these are only the interim results of the study, they are very encouraging, the scientists say. Of the nine children, seven developed seemingly healthy immune systems, which were able to fight off bacterial and viral infections contracted before treatment. One boy, who received a lower dose of virus, did not seem to rebuild his immune system after the gene therapy, so instead received a successful cord blood stem cell transplant. The last child died from a pre-existing viral infection before the new immune cells had time to properly develop.

None of the children enrolled have developed leukaemia, although they will be monitored throughout childhood to see whether the risk has been entirely removed. If this treatment turns out to be both effective and safe in the long-term, researchers hope that it could be applied to a number of other genetic childhood diseases.

SOURCES & REFERENCES
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
New England Journal of Medicine |  9 October 2014
Gene therapy effective to treat 'bubble boy' syndrome
BBC News |  9 October 2014
Gene Therapy for SCID-X1 Safer in Second Iteration
Medscape |  9 October 2014
Gene-Therapy Trial for ‘Bubble Boy Syndrome’ Shows Promise
Wall Street Journal |  8 October 2014
New gene therapy for 'bubble boy' disease appears effective, safe, study in NEJM reports
EurekAlert! (press release) |  8 October 2014
New gene therapy treatment showing promise against 'bubble boy' disease
Reuters |  8 October 2014
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
29 April 2019 - by Dr Helen Robertson 
Infants born with a severe immunodeficiency disorder have been successfully treated in a new gene therapy trial...
30 October 2017 - by Jen Willows 
NICE has approved a gene therapy for children with a rare disorder that leaves them with no functioning immune system...
7 December 2016 - by Dr Loredana Guglielmi 
Researchers have developed a stem cell test that could rapidly predict how patients with acute myeloid leukaemia will respond to treatment...
11 April 2016 - by Rebecca Carr 
A gene therapy for children with a rare but life-threatening genetic disorder that severely weakens the immune system has been recommended for approval by the European Medicines Agency...
14 December 2015 - by Dr James Heather 
Two patients enrolled in a clinical trial of a gene therapy to treat severe congenital immunodeficiency have shown signs of substantial improvement in their condition...
5 March 2012 - by Ayesha Jadoon 
Early trials in patients with chronic granulomatous disorder (x-CGD), a recessive X-linked condition that affects the immune system, have shown signs of success following the use of gene therapy. The observed boost in immunity of those undergoing treatment was only temporary, however, and the faulty gene causing x-CGD was not corrected permanently....
30 August 2011 - by Rosemary Paxman 
Over a dozen children with 'boy in bubble' syndrome are alive and well, with functioning immune systems, nine years after undergoing gene therapy to correct their disorder, researchers report....
7 January 2008 - by Stuart Scott 
A boy enrolled on a pioneering gene therapy trial has developed leukaemia, his doctors based at London's Great Ormond Street Hospital have announced. The three-year-old was of one of 10 patients treated for X-SCID: a genetic disorder whereby a mutation in the IL2RG gene leaves carriers without...
27 April 2006 - by BioNews 
Replacement genes used to treat an inherited immune disorder could trigger cancer, new research carried out on rodents suggests. The study, published in the journal Nature, shows that treating mice with a normal copy of the gene defective in X-linked severe combined immune deficiency (X-SCID) results in cancer of the...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.